Tirabrutinib was approved in March 2020 in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. In addition, tirabrutinib is in clinical development by Ono Pharmaceutical and Gilead Sciences in the United States, Europe, and Japan for autoimmune disorders, chronic lymphocytic leukemia, B cell lymphoma, Sjogren’s syndrome, pemphigus, and rheumatoid arthritis.<\/p>\n
Tirabrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase.<\/p>\n
To access tirabrutinib-tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n
Velexbru\u00ae Tablet 80mg, a BTK Inhibitor, for Additional Indication of\u00a0 Waldenstrom Macroglobulinemia and Lymphoplasmacytic Lymphoma.\u00a0Velexbru (tirabrutinib hydrochloride) is a medication used for the treatment of recurrent or refractory primary central nervous system lymphoma.<\/p>\n
Facts about tirabrutinib-tablets<\/strong><\/p>\n Disease Indications-Lymphoma If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import “tirabrutinib-tablets\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Ono Pharmaceutical Co., Ltd.
\nUsage-Oral
\nMedicine Approved By-Pharmaceuticals and Medical Devices Agency (PMDA)
\nSummary of FDA-approved use on approval date: Click Here
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n